UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Annals of oncology, 2018-03, Vol.29 (3), p.646-653

2018

Volltextzugriff (PDF)

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

European journal of cancer (1990), 2019-06, Vol.114, p.128-136

2019

Volltextzugriff (PDF)

Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter

Genes & development, 2001-08, Vol.15 (16), p.2042-2047

2001

Volltextzugriff (PDF)

Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-07-09

2017

Volltextzugriff (PDF)

Dataset for the paper "Designs in finite classical polar spaces"

2024

Volltextzugriff (PDF)

Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD3-06-PD3-06

2018

Volltextzugriff (PDF)

Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy

European journal of cancer (1990), 2018-04, Vol.92, p.S15

2018

Volltextzugriff (PDF)

22 - Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy

European journal of cancer (1990), 2018-04, Vol.92, p.S15-S15

2018

Volltextzugriff (PDF)

59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening

Annals of oncology, 2016-12, Vol.27, p.ix17-ix17

2016

Volltextzugriff (PDF)

59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.S5-S5-1

2012

Volltextzugriff (PDF)

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S5-S5-03

2016

Volltextzugriff (PDF)

Biomarker (BM) Analyses of a Phase II Study of Neoadjuvant Pertuzumab and Trastuzumab With and Without Anthracycline (ATC)-Containing Chemotherapy for Treatment of HER2-Positive Early Breast Cancer (BC) (Tryphaena)

Annals of oncology, 2012-09, Vol.23, p.ix83

2012

Volltextzugriff (PDF)

Exploratory biomarker assessment in the Trastuzumab for Gastric Cancer (ToGA) study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e21029-e21029

2011

Volltextzugriff (PDF)

P5-22-01: Feasibility and Patient Safety of Serial Biopsies (bx) in Metastatic HER2−Positive Breast Cancer (BC) To Evaluate Alterations in Molecular Biomarkers (BM): Preliminary Results of SHERsig (Study of HER2 Signature in Metastatic Breast Cancer) a Prospective Phase II Study

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-22-01

2011

Volltextzugriff (PDF)

S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC)

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.S5-S5-1

2011

Volltextzugriff (PDF)

Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events

The EMBO journal, 2000-11, Vol.19 (21), p.5813-5823

2000

Volltextzugriff (PDF)

Transcriptional control: Calling in histone deacetylase

Current biology, 1997-08, Vol.7 (8), p.R505-R507

1997

Volltextzugriff (PDF)

DNA binding of USF is required for specific E-box dependent gene activation in vivo

Oncogene, 1999-12, Vol.18 (51), p.7200-7211

1999

Volltextzugriff (PDF)

Repression of p15INK4b expression by Myc through association with Miz-1

Nature cell biology, 2001-04, Vol.3 (4), p.392-399

2001

Volltextzugriff (PDF)

Repression of p15 super(INK4b) expression by Myc through association with Miz-1

Nature cell biology, 2001-04, Vol.3 (4), p.392-399

2001

Volltextzugriff (PDF)

Classification of Δ-Divisible Linear Codes Spanned by Codewords of Weight Δ

IEEE transactions on information theory, 2023-06, Vol.69 (6), p.3544-3551

2023

Volltextzugriff (PDF)

On the Lengths of Divisible Codes

IEEE transactions on information theory, 2020-07, Vol.66 (7), p.4051-4060

2020

Volltextzugriff (PDF)

On α-points of q-analogs of the Fano plane

Designs, codes, and cryptography, 2022, Vol.90 (6), p.1335-1345

Kiermaier, Michael

2022

Volltextzugriff (PDF)

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(180)
Mit Volltextzugriff
(197)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(218)
Japanisch
(21)
Deutsch
(2)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(127)
Physical Sciences
(76)
Physics
(47)
Technology
(46)
Life Sciences & Biomedicine
(39)
Mathematics
(29)
Engineering
(28)
Humans
(27)
Computer Science
(22)
Engineering, Electrical & Electronic
(22)
Physics, Applied
(22)
Exact Sciences And Technology
(17)
Oncology
(17)
Female
(15)
Mathematics, Applied
(15)
Chemistry
(13)
Physics, Particles & Fields
(13)
Computer Science, Theory & Methods
(12)
Animals
(10)
Circuits
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter

Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Dataset for the paper "Designs in finite classical polar spaces"

Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC)

Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy

22 - Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy

59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening

59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening

Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

Biomarker (BM) Analyses of a Phase II Study of Neoadjuvant Pertuzumab and Trastuzumab With and Without Anthracycline (ATC)-Containing Chemotherapy for Treatment of HER2-Positive Early Breast Cancer (BC) (Tryphaena)

Exploratory biomarker assessment in the Trastuzumab for Gastric Cancer (ToGA) study

P5-22-01: Feasibility and Patient Safety of Serial Biopsies (bx) in Metastatic HER2−Positive Breast Cancer (BC) To Evaluate Alterations in Molecular Biomarkers (BM): Preliminary Results of SHERsig (Study of HER2 Signature in Metastatic Breast Cancer) a Prospective Phase II Study

S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC)

Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events

Transcriptional control: Calling in histone deacetylase

DNA binding of USF is required for specific E-box dependent gene activation in vivo

Feasibility and Patient Safety of Serial Biopsies (bx) in Metastatic HER2-Positive Breast Cancer (BC) To Evaluate Alterations in Molecular Biomarkers (BM): Preliminary Results of SHERsig (Study of HER2 Signature in Metastatic Breast Cancer) a Prospective Phase II Study

Repression of p15INK4b expression by Myc through association with Miz-1

Repression of p15 super(INK4b) expression by Myc through association with Miz-1

Classification of Δ-Divisible Linear Codes Spanned by Codewords of Weight Δ

On the Lengths of Divisible Codes

On α-points of q-analogs of the Fano plane

Suchergebnisse filtern